View abstract

Cet abstract a été assigné à sessions
TitreOzurdex implant migration into the Anterior chamber
ButOzurdex (Allergan Inc, Irvine, CA, USA) is a biodegradable sustained release device containing 0.7 mg of dexamethasone in a solid polymer drug delivery system. It is approved for the management of macular oedema associated with central and branch retinal vein occlusion, diabetic macular oedema and non-infectious uveitis. With increasing use of this non-tethered steroid implant we continue to learn about potential risks associated with the treatment and thus learn about considerations prior to starting such a treatment and also how to manage such complications should they arise.
MéthodesHere we present a case of a 61 year old male who unfortunately developed one of the rarer complications of an Ozurdex implant. 11 days following the implant, the patient noticed the implant in the anterior chamber of his eye leading to corneal endothelium decompensation, and thus the deterioration in his vision
Résultatsthe patient continued to have corneal oedema due to endothelial cell loss
ConclusionWe review the risk factors of Ozurdex implant migration, and how to manage the patients that develop such a complication
Conflit d'intérêtNon
Auteur 1
NomNARDEOSINGH
InitialesS
InstitutOphthalmology
VilleGlasgow
Auteur 2
NomElhassan
InitialesS
InstitutOphthalmology
VilleCardiff
Auteur 3
NomWilliams
InitialesG
InstitutOphthalmology
VilleSwansea
Auteur 4
NomHill
InitialesR
InstitutOphthalmology
VilleSwansea
top ^